Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma

被引：0
|
作者：
Eisenhardt, A. [1 ,2 ]
Ohlmann, C-H [3 ]
Doehn, C. [4 ,5 ]
机构：
[1] Praxiskliniken Urol Rhein Ruhr, Schulstr 11, D-45468 Mulheim, Germany
[2] Univ Klinikum Essen, Klin & Poliklin Urol Kinderurol & Uroonkol, Essen, Germany
[3] Malteser Krankenhaus Seliger Gerhard Bonn, Klin Urol, Bonn, Germany
[4] Urologikum Lubeck, Lubeck, Germany
[5] Deutsch Uroonkologen D Uo, Berlin, Germany
来源：
UROLOGE | 2020年 / 59卷 / 05期
关键词：
Androgene deprivation; Combination therapy; Drug-related side effects; Chemotherapy; Hormone suppression; METASTATIC UROTHELIAL CARCINOMA; CISPLATIN-INELIGIBLE PATIENTS; PHASE-III TRIAL; PLUS PREDNISONE; SINGLE-ARM; ANDROGEN-DEPRIVATION; VINFLUNINE PLUS; SUPPORTIVE CARE; SURVIVAL; MULTICENTER;
D O I：
10.1007/s00120-020-01182-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Systemic therapy in uro-oncology is currently undergoing major changes. In the past, drug therapies only showed good treatment results in metastasized testicular tumors. New developments indicate that an improved understanding of tumor biology will lead to targeted treatment strategies for metastatic prostate, urothelial and renal cell carcinoma. In the following article, we summarize the practice-relevant innovations in systemic therapy in the guidelines on prostate cancer, transitional cell carcinoma of the bladder and renal cell carcinoma.
引用
收藏
页码：533 / 542
页数：10
相关论文
共 50 条
  • [41] Transitional cell carcinoma in a renal allograft
    I. Vervloessem
    R. Oyen
    Y. Vanrenterghem
    H. Van Poppel
    P. Van Hover
    G. Debakker
    A. L. Baert
    European Radiology, 1998, 8 : 936 - 938
  • [42] Transitional cell carcinoma in a renal allograft
    Vervloessem, I
    Oyen, R
    Vanrenterghem, Y
    Van Poppel, H
    Van Hover, P
    Debakker, G
    Baert, AL
    EUROPEAN RADIOLOGY, 1998, 8 (06) : 936 - 938
  • [43] TRANSITIONAL CELL-CARCINOMA - CAUSE OF REFRACTORY CANCER OF PROSTATE
    WENDELKEN, JR
    SCHELLHAMMER, PF
    LADAGA, LE
    ELMAHDI, AM
    UROLOGY, 1979, 13 (05) : 557 - 560
  • [44] Renal small cell carcinoma (neuroendocrine carcinoma) without features of transitional cell carcinoma
    Masuda, T
    Oikawa, H
    Yashima, A
    Sugimura, J
    Okamoto, T
    Fujioka, T
    PATHOLOGY INTERNATIONAL, 1998, 48 (05) : 412 - 415
  • [45] A case of renal transitional cell carcinoma associated with synchronous contralateral renal cell carcinoma
    Hong, SK
    Jeong, SJ
    Lee, SE
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2001, 16 (01) : 108 - 110
  • [46] Combination Systemic Therapy for Advanced Renal Cell Carcinoma
    Miller, Rowan E.
    Larkin, James M. G.
    ONCOLOGIST, 2009, 14 (12): : 1218 - 1224
  • [47] Is tailored systemic therapy in renal cell carcinoma realistic?
    Kondo, Tsunenori
    LANCET ONCOLOGY, 2022, 23 (05): : 555 - 557
  • [48] Response of Primary Renal Cell Carcinoma to Systemic Therapy
    Bosse, Dominick
    Lin, Xun
    Simantov, Ronit
    Lalani, Aly-Khan A.
    Derweesh, Ithaar
    Chang, Steven L.
    Choueiri, Toni K.
    Mckay, Rana R.
    EUROPEAN UROLOGY, 2019, 76 (06) : 852 - 860
  • [49] Systemic Therapy in Renal Cell Carcinoma: Advancing Paradigms
    Posadas, Edwin M.
    Figlin, Robert A.
    ONCOLOGY-NEW YORK, 2012, 26 (03): : 290 - 301
  • [50] Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma
    Kenney, Patrick A.
    Wood, Christopher G.
    UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (02) : 211 - +
12345